转铁蛋白-转铁蛋白受体系统在药物运输中的应用

转铁蛋白-转铁蛋白受体系统在药物运输中的应用

夏青, 杨秀伟, 杨晓达^*, 钱忠明, 王夔

1. 北京大学药学院化学生物学系, 北京 100191

2. 北京大学天然药物及仿生药物国家重点实验室, 北京 100191

3. 香港理工大学应用生物和化学技术系铁代谢实验室, 香港

收稿日期:2008-11-10 修回日期:2009-02-10 出版日期:2009-03-15 发布日期:2009-03-15
通讯作者: 杨晓达*

Drug delivery via the transferrin receptor-mediated endocytosis pathway

Qing Xia, Xiu-Wei Yang, Xiao-Da Yang^*, Zhong-Ming Qian, Kui Wang

1. Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
2. The State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
3. Laboratory of Iron Metabolism, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong

Received:2008-11-10 Revised:2009-02-10 Online:2009-03-15 Published:2009-03-15
Contact: Xiao-Da Yang*

摘要/Abstract

摘要： 膜转铁蛋白受体介导的内吞作用应用于新的药物靶向给药系统, 包括将抗肿瘤药物, 蛋白和治疗基因定位运输至恶性增殖细胞或是中枢神经系统。通过偶联转铁蛋白或其抗体连接到转铁蛋白受体上成为治疗的药物或转运载体。多种药物载体如脂质体, 纳米颗粒与DNA复合物用于高效运输治疗物。转铁蛋白复合物的运用不仅提高了药效, 改善了选择性与药物释放性能, 降低了毒性, 同时也延长药物血浆半衰期, 提高药物主动靶性。本篇综述介绍了转铁蛋白/转铁蛋白受体介导的药物运输的研究进展。

关键词: 转铁蛋白, 转铁蛋白, 转铁蛋白, 转铁蛋白受体, 转铁蛋白受体, 转铁蛋白受体, 药物运输, 药物运输, 药物运输

Abstract:

The membrane transferrin receptor-mediated endocytosis has been exploited for developing novel targeted drug delivery systems, which could have a variety of applications in the site-specific delivery of anticancer drugs, proteins and therapeutic genes into proliferating malignant cells that overexpress the transferrin receptors. This is achieved by coupling transferrin or monoclonal antibody to transferrin receptor with therapeutic drugs or drug delivery vesicles. The transferrin conjugates can be obtained by use of either bifunctional chemical linkers or by genetic infusion of therapeutic peptides/proteins into the structure of transferrin / and monoclonal antibody to transferrin receptor. A variety of drug carriers such as liposomes, nanoparticles and DNA-polymer complexes (i.e. polyplex and lipoplex) were used to efficiently deliver the transferrin conjugates. Use of transferrin conjugates results in improvement in drug efficacy, selectivity and drug release as well as reduction in drug toxicity. This paper reviews the basic biochemistry of transferrin and the transferrin receptor as well as the strategy for developing targeted drug delivery system.

Key words: Transferrin, Transferrin, Transferrin receptor, Transferrin receptor, Drug delivery, Drug delivery

中图分类号:

Supporting:

Foundation items: National High Technology Research and Development Program of China (Grant No.2004AA2Z3783), Beijing Municipal Special-purpose Science Foundation of China (Grant No.Z0004105040311).
^*Corresponding author. Tel.: 86-10-86583631

夏青, 杨秀伟, 杨晓达^*, 钱忠明, 王夔

转铁蛋白-转铁蛋白受体系统在药物运输中的应用

[J]. .

Qing Xia, Xiu-Wei Yang, Xiao-Da Yang^*, Zhong-Ming Qian, Kui Wang

. Drug delivery via the transferrin receptor-mediated endocytosis pathway[J]. .

参考文献

[1] Langer, R. Nature. 1998, 392, 5-10.
[2] Vyas, S.P.; Singh, A.; Sihorkar, V. Crit. Rev. Ther. Drug. Carrier. Syst. 2001, 18, 1-76.
[3] Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Pharmacol. Rev. 2002, 54, 561-587.
[4] Tanaka, T.; Shiramoto, S.; Hanano, S.; Kaneo, Y. Int. J. Pharm. 2004, 277, 36-39.
[5] Shen, X.; Zhu, H.; He, F.; Xing, W.; Li, L.; Liu, J.; Yang, J.; Pan, X.; Lei, P.; Wang, Z.; Shen G. Int. Immunopharmacol. 2008, 8, 1813-1820.
[6] Sun, H.; Li, H.; Sadler, P.J. Chem. Rev. 1999, 99, 2817-2842.
[7] Zhong, W.; Parkinson, J.A.; Guo, M.; Sadler, P.J. J. Biol. Inorg. Chem. 2002, 7, 589-599.
[8] Qian, Z.M.; Liao, Q.K.; To, Y.; Ke, Y.; Tsoi, Y.K.; Wang, G.F.; Ho, K.P. Cell. Mol. Biol. 2000, 46, 541-548.
[9] Inoue, T.; Cavanaugh, P.G.; Steck, P.A.; Brünner, N.; Nicolson, G.L. J. Cell. Physiol. 1993, 156, 212-217.
[10] Kawabata, H.; Germain, R.S.; Vuong, P.T.; Nakamaki, T.; Said, J.W.; Koeffler, H.P. J. Biol. Chem. 2000, 275, 16618-16625.
[11] Roetto, A.; Totaro, A.; Piperno, A.; Piga, A.; Longo, F.; Garozzo, G.; Calì, A.; De Gobbi, M.; Gasparini, P.; Camaschella, C. Blood. 2001, 97, 2555-2560.
[12] Girelli, D.; Bozzini, C.; Roetto, A.; Alberti, F.; Daraio, F.; Colombari, R.; Olivieri, O.; Corrocher, R.; Camaschella, C. Gastroenterology. 2002, 122, 1295-1302.
[13] West, A.P.; Bennett, M.J.; Sellers, V.M.; Andrews, N.C.; Enns, C.A.; Bjorkman, P.J. J. Biol. Chem. 2000, 275, 38135-38138.
[14] Lieu, P.T.; Heiskala, M.; Peterson, P.A.; Yang, Y. Mol. Aspects Med. 2001, 22, 1-87.
[15] Daniels, T.R.; Delgado, T.; Helguera, G.; Penichet, M.L. Clin. Immunol. 2006, 121, 159-176.
[16] Harris, W.R.; Chen, Y.; Wein, K. Inorg. Chem. 1994, 33, 4991-4998.
[17] Li, Y.Q.; Liu, B.; Zhao, C.G.; Zhang, W.; Yang, B.S. Clin. Chim. Acta. 2006, 366, 225-232.
[18] Zhang, L.; Szeto, K.Y.; Wong, W.B.; Loh, T.T.; Sadler, P.J.; Sun, H. Biochemistry. 2001, 40, 13281-13287.
[19] Smith, C.A.; Sutherland-Smith, A.J.; Keppler, B.K.; Kratz, F.; Baker, E.N.; Keppler, B.H. J. Biol. Inorg. Chem. 1996, 1, 424-443.
[20] Guo, M.; Sadler, P.J. J. Chem. Soc. Dalton Trans. 2000, 1, 7-9.
[21] Ali, S.A.; Joao, H.C.; Hammerschmid, F.; Eder, J.; Steinkasserer, A. J. Biol. Chem. 1999, 274, 24066-24073.
[22] Asai, T.; Trinh, R.; Ng, P.P.; Penichet, M.L.; Wims, L.A.; Morrison, S.L. Biomol. Eng. 2005, 21, 145-155.
[23] Pardridge, W.M. Adv. Drug Deliv. Rev. 1999, 36, 299-321.
[24] Kratz, F.; Beyer, U.; Roth, T.; Tarasova, N.; Collery, P.; Lechenault, F.; Cazabat, A.; Schumacher, P.; Unger, C.; Falken, U. J. Pharm. Sci. 1998, 87, 338-346.
[25] Lai, B.T.; Gao, J.P.; Lanks, K.W. Cancer Chemother. Pharmacol. 1998, 41, 155-160.
[26] Sizensky, J.A.; Barabas, K.; Faulk, W.P. Am. J. Reprod. Immunol. 1992, 27, 163-166.
[27] Eavarone, D.A.; Yu, X.; Bellamkonda, R.V. J. Biomed. Mater. Res. 2000, 51, 10-14.
[28] Dufes, C.; Muller, J.M.; Couet, W.; Olivier, J.C. Pharm. Res. 2004, 21, 101-107.
[29] Kobayashi, T.; Ishida, T.; Okada, Y.; Ise, S.; Harashima, H.; Kiwada, H. Int. J. Pharm. 2007, 329, 94-102.
[30] Hagihara, H.; Walbridge, S.; Olson, A.W.; Oldfield, E.H.; Youle, R.J. Cancer Res. 2000, 60, 230-234.
[31] Laske, D.W.; Youle, R.J.; Oldfield, E.H. Nat. Med. 1997, 3, 1362-1368.
[32] Xia, C.Q.; Wang, J.; Shen, W.C. J. Pharmcol. Exp. Ther. 2000, 295, 594-600.
[33] Suzuki, R.; Takizawa, T.; Kuwata, Y.; Mutoh, M.; Ishiguro, N.; Utoguchi, N.; Shinohara, A.; Eriguchi, M.; Yanagie, H.; Maruyama, K. Int. J. Pharm. 2008, 346, 143-150.
[34] Beyer, U.; Roth, T.; Schumacher, P.; Maier, G.; Unold, A.; Frahm, A.W.; Fiebig, H.H.; Unger, C.; Kratz, F. J. Med. Chem. 1998, 41, 2701-2708.
[35] Liao, W.P.; DeHaven, J.; Shao, J.; Chen, J.X.; Rojanasakul, Y.; Lamm, D.L.; Ma, J.K.H. Drug Deliv. 1998, 5, 111-118.
[36] Xu, Z.; Gu, W.; Huang, J.; Sui, H.; Zhou, Z.; Yang, Y.; Yan, Z.; Li, Y. Int. J. Pharm. 2005, 288, 361-368.
[37] Sahoo, S.K.; Ma, W.; Labhasetwar, V. Int. J. Cancer. 2004, 112, 335-340.
[38] Nakase, I.; Lai, H.; Singh, N.P.; Sasaki, T. Int. J. Pharm. 2008, 354, 28-33.
[39] Singh, M.; Atwal, H.; Micetich, R. Anticancer Res. 1998, 18, 1423-1428.
[40] Fritzer, M.; Szkeres, T.; Szüts, V.; Jarayam, H.N.; Goldenberg, H. Biochem. Pharmcol. 1996, 52, 489-493.
[41] Weaver, M.; Laske, D.W. J. Neurooncol. 2003, 65, 3-13.
[42] Maruyama, K.; Ishida, O.; Kasaoka, S.; Takizawa, T.; Utoguchi, N.; Shinohara, A.; Chiba, M.; Kobayashi, H.; Eriguchi, M.; Yanagie, H. J. Controlled Release. 2004, 98, 195-207.
[43] Hatakeyama, H.; Akita, H.; Maruyama, K.; Suhara, T.; Harashima, H. Int. J. Pharm. 2004, 281, 25-33.
[44] Pun, S.H.; Tack, F.; Bellocq, N.C.; Cheng, J.; Grubbs, B.H.; Jensen, G.S.; Davis, M.E.; Brewster, M.; Janicot, M.; Janssens, B.; Floren, W.; Bakker, A. Cancer Biol. Ther. 2004, 3, 641-650.
[45] Kakudo, T.; Chaki, S.; Futaki, S.; Nakase, I.; Akaji, K.; Kawakami, T.; Maruyama, K.; Kamiya, H.; Harashima, H. Biochemistry. 2004, 43, 5618-5628.
[46] Lim, C.J.; Shen, W.C. Pharm. Res. 2004, 21, 1985-1992.
[47] Shimbo, T.; Kawachi, M.; Saga, K.; Fujita, H.; Yamazaki, T.; Tamai, K.; Kaneda, Y. Biochem. Biophys. Res. Commun. 2007, 364, 423-428.
[48] Kursa, M.; Walker, G.F.; Roessler, V.; Ogris, M.; Roedl, W.; Kircheis, R.; Wagner, E. Bioconjug. Chem. 2003, 14, 222-231.
[49] Duncan, R. Anticancer Drugs. 1992, 3, 175-210.
[50] Cotton, M.; Wagner, E.; Birnstiel, M.L. Method. Enzymol. 1993, 217, 618-644.
[51] Lasic, D.D.; Templeton, N.S. Adv. Drug Deliv. Rev. 1996, 20, 221-266.
[52] Yanagihara, K.; Cheng, H.; Cheng, P.W. Cancer Gene Ther. 2000, 7, 59-65.
[53] Kono, K.; Torikoshi, Y.; Mitsutomi, M.; Itoh, T.; Emi, N.; Yanagie, H.; Takagishi, T. Gene Ther. 2001, 8, 5-12.
[54] Xu, L.; Frederik, P.; Pirollo, K.F.; Tang, W.H.; Rait, A.; Xiang, L.M.; Huang, W.; Cruz, I.; Yin, Y.; Chang, E.H. Hum. Gene Ther. 2002, 13, 469-481.
[55] Sato, Y.; Yamauchi, N.; Takahashi, M.; Sasaki, K.; Fukaura, J.; Neda, H.; Fujii, S.; Hirayama, M.; Itoh, Y.; Koshita, Y.; Kogawa, K.; Kato, J.; Sakamaki, S.; Niitsu, Y. FASEB. J. 2000, 14, 2108-2118. [56] Salem, A.K.; Searson, P.C.; Leong, K.W. Nat. Mater. 2003, 2, 668-671.
[57] Xia, C.Q.; Shen, W.C. Pharm. Res. 2001, 18, 191-195.
[58] Widera, A.; Kim, K.J.; Crandall, E.D.; Shen, W.C. Pharm. Res. 2003, 20, 1231-1238.
[59] Vinogradov, S.V.; Batrakova, E.V.; Kabanov, A.V. Bioconjug. Chem. 2004, 15, 50-60.